Study Title
Phase 3 Trial of Copper Cu 64 PSMA I&T PET/CT Imaging in Men with Suspected Biochemical Recurrence of Prostate Cancer (Solar-Recur)
Study Details
Description:
Solar-Recur is a single-arm prospective study. Local read of the copper Cu 64 PSMA I&T PET/CT can be used to inform patient management. For the primary endpoints, PET/CT scans will be read by blinded independent reviewers.
Sponsor:
CuriumContacts:
Darcy Denner, Ph.D. (Clinical Trial Director)darcy.denner@curiumpharma.com
Government Study Link:
NCT062356099 - Click here to see study onClinicalTrials.gov
Inclusion
- BCR of PC: Patients w/prior RP: PSA >.2 ng/mL w/confirm PSA value >.2, or w/prior radiation: 2ng/mL PSA rise over nadir
- Male aged ≥18 years
- Prior RP (>6 weeks prior to screening) or radiation therapy (>1 year prior to screening) with curative intent
- Histologically proven prostate adenocarcinoma
Exclusion
- ADT or other therapies targeting the Androgen pathway within 3 months. Pts w/rise in PSA while on ADT for >6 months
- PSMA PET within 90 days prior to enrollment
Patient Education
Publications
Publications Not Yet Provided
Locations
United States
© 2021 XCancer Software LLC
Contact XCancer: 402-991-8468